Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes

Rosangela Invernizzi, Alessandro Pecci, Erica Travaglino, Paolo G. Gobbi, Lucia Malabarba, Isabella Ramajoli, Edoardo Ascari

Research output: Contribution to journalArticle

Abstract

We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m2 i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.

Original languageEnglish
Pages (from-to)246-250
Number of pages5
JournalBritish Journal of Haematology
Volume118
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Amifostine
Myelodysplastic Syndromes
Bone Marrow
Refractory Anemia with Excess of Blasts
Reticulocyte Count
Hematopoiesis
Platelet Count
Neutrophils
Therapeutics
In Vitro Techniques

Keywords

  • Amifostine
  • Apoptosis
  • Haematopoietic progenitors
  • Myelodysplastic syndrome
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. / Invernizzi, Rosangela; Pecci, Alessandro; Travaglino, Erica; Gobbi, Paolo G.; Malabarba, Lucia; Ramajoli, Isabella; Ascari, Edoardo.

In: British Journal of Haematology, Vol. 118, No. 1, 2002, p. 246-250.

Research output: Contribution to journalArticle

Invernizzi, R, Pecci, A, Travaglino, E, Gobbi, PG, Malabarba, L, Ramajoli, I & Ascari, E 2002, 'Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes', British Journal of Haematology, vol. 118, no. 1, pp. 246-250. https://doi.org/10.1046/j.1365-2141.2002.03569.x
Invernizzi, Rosangela ; Pecci, Alessandro ; Travaglino, Erica ; Gobbi, Paolo G. ; Malabarba, Lucia ; Ramajoli, Isabella ; Ascari, Edoardo. / Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. In: British Journal of Haematology. 2002 ; Vol. 118, No. 1. pp. 246-250.
@article{06d9dbfdbd7441a1a509c8e2b0bcbfcd,
title = "Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes",
abstract = "We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m2 i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.",
keywords = "Amifostine, Apoptosis, Haematopoietic progenitors, Myelodysplastic syndrome, Therapy",
author = "Rosangela Invernizzi and Alessandro Pecci and Erica Travaglino and Gobbi, {Paolo G.} and Lucia Malabarba and Isabella Ramajoli and Edoardo Ascari",
year = "2002",
doi = "10.1046/j.1365-2141.2002.03569.x",
language = "English",
volume = "118",
pages = "246--250",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes

AU - Invernizzi, Rosangela

AU - Pecci, Alessandro

AU - Travaglino, Erica

AU - Gobbi, Paolo G.

AU - Malabarba, Lucia

AU - Ramajoli, Isabella

AU - Ascari, Edoardo

PY - 2002

Y1 - 2002

N2 - We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m2 i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.

AB - We treated six patients with primary myelodysplastic syndrome (MDS) with amifostine (200 mg/m2 i.v./three times a week for three consecutive weeks). Neutrophil counts were more frequently increased than platelet and reticulocyte counts, but no reduction of the transfusion requirement was observed. Significant reduction of the marrow blasts was observed in one case of refractory anaemia with excess of blasts. In vitro stimulation of haematopoiesis was observed in five cases. The apoptotic rate of marrow cells was significantly diminished even after the first course. Our findings show fairly good clinical and biological response to amifostine in MDS.

KW - Amifostine

KW - Apoptosis

KW - Haematopoietic progenitors

KW - Myelodysplastic syndrome

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036064938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036064938&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03569.x

DO - 10.1046/j.1365-2141.2002.03569.x

M3 - Article

C2 - 12100155

AN - SCOPUS:0036064938

VL - 118

SP - 246

EP - 250

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -